6 Best Practices for Enhancing Scientific Exchanges

Technology can help MSLs to quickly unearth new data, in real time, gaining the ability to quickly see trends and patterns that can make a difference in the engagements with experts. Here are six best practices to help you save time and achieve greater impact. READ MORE
6 Best Practices for Enhancing Scientific Exchanges

Medmeme to become Pharmaspectra

A new company with a broader mission and product set, the name Pharmaspectra better communicates our goal of solving problems across the biopharma spectrum, from drug discovery through post-marketing.
READ MORE
Medmeme to become Pharmaspectra

Pharmacy Benefit Managers Targeted by Gottlieb

Pharmacy benefits managers (PBMs), private firms that contract with health insurers to process and administer claims, are an integral part of the current pharmaceutical administration process. However, some of the current practices of PBMs have drawn significant criticism.
READ MORE
Pharmacy Benefit Managers Targeted by Gottlieb

8 Red Flags of a Predatory Medical Conference

Bogus data. Pay-for-play. And even fake news. Illegitimate science has taken several forms. The most notable of all: predatory publishing. But another, less discussed, issue is the problem of predatory medical conferences. And there are costs.
READ MORE
8 Red Flags of a Predatory Medical Conference

Characteristics of the Younger MD

A key demographic trend has begun to play out in medicine: a wave of younger doctors entering the field. there’s been an uptick in the number of physicians under age 40, along with an 8 percent spike in medical school enrollments between 2012 and 2016, but what sets them apart?
READ MORE
Characteristics of the Younger MD

What New FDA Guidance Documents May Mean for Pharma

Back in October, the Food and Drug Administration (FDA) published a series of documents regarding Abbreviated New Drug Applications (ANDAs) for the “genericization” of drugs, with an emphasis placed on simplifying the process by which companies can produce generic versions of complex drugs. Here is your guide.
READ MORE
What New FDA Guidance Documents May Mean for Pharma

Kymriah and the Outcomes-Based Contract: Is this a Trend?

Is the outcomes based contract agreed for Kymriah the beginning of a trend? The one-time drug has a hefty price tag of $475,000, but Novartis will only receive payment from CMS if patients show significant improvement. Are these contracts a good way of sharing risk and ensuring wider access to novel therapies?
READ MORE
Kymriah and the Outcomes-Based Contract: Is this a Trend?

The Medical Continuum

Safe Harbor prohibits much of the communication between commercial operations and Medical Affairs; publication planners may not be able to easily access the R&D work that has come before; regional affiliates may be presenting posters at meetings independent of headquarters. Can your organization see the full picture?
READ MORE
The Medical Continuum

The Myth of Data Permanence

Data Really Isn’t Permanent Cyber specialists warn that once something appears on the Internet, it’s there forever. That’s probably truer for salacious photos of pop stars than it is for corporate or government data, though. In scientific communications, unless you collect data as it’s published, you may not be able to retrieve the information you want when you need it.
READ MORE
The Myth of Data Permanence - Medmeme

Dedicated Field Medical Metrics

Historically, Medical Affairs has primarily served a supportive role. Today, it’s becoming a strategic advantage. Filtering information and experts helps Field Medical teams reduce their preparation time up to an estimated 75 percent, to maximize valuable resources.
READ MORE
agenda banner

CITATION: PD-L1/PD-1 Inhibitors and Beyond

A peer-reviewed article that appeared in the Journal of Pharmacology and Clinical Research by David Segarnick, PhD and Heather Chien, M.S., explores the current and future landscape of immunotherapy compounds that use the body's own immune system to fight cancer, citing Medmeme data
READ MORE
CITATION:  PD-L1/PD-1 Inhibitors and Beyond

Strategic Metrics Dedicated to Medical Affairs

Metrics that bridge the gap to Medical Affairs 2.0-Historically, decisions for the generation and placement of Medical Affairs data were based on experience and instinct simply because hard, objective information was not available and end-to-end metrics for evaluation simply did not exist. Medical Affairs is in the process of evolving from a traditional support role into a more strategic one that requires a dedicated set of data and analytics
READ MORE
analytics

PRESS: Harnessing the Unrivaled Power of Key Opinion Leaders

This month's Pharmaceutical Market Europe Magazine features a thought leadership article from Medmeme.  The article discusses the importance of Medical Affairs engaging thought leaders and KOLs early  - not waiting until phase III trials - to drive Share of Scientific Voice and successful launches.
READ MORE
PRESS: Harnessing the Unrivaled Power of Key Opinion Leaders

Are You Being Heard?

Is it better for your scientific paper to appear in JAMA or the New England Journal of Medicine? Should you present your research at a specialty meeting like the Annual Meeting of the Society for Immunotherapy of Cancer or choose a more general conference like the American Society of Clinical Oncology (ASCO)? How you answer those questions affects the impact of your scientific dissemination – your ability to present information to key thought leaders and receive attention from the scientific community.
READ MORE
Are You Being Heard?

Never Gonna Give You Up

One thing that data providers are quickly finding out is that maintaining complete, compliant and updated information on Scientific Experts is hard, especially at an enterprise level for a Medical Affairs organization
READ MORE
Never Gonna Give You Up

PRESS: A World of Content, In Context

Medmeme has been featured this week in GEN – Genetic Engineering and Biotechnology News! An in-depth interview with Medmeme’s CEO, Mahesh Naithani, who describes the particular challenges the pharmaceutical industry has in terms of accessing the right data
READ MORE
PRESS: A World of Content, In Context

Big data’s big potential

As the ocean of data gathered from research studies, wearables and medtech continues to spiral, the pharma industry is faced with a conundrum: what data are actually relevant, how can we access them easily and how do we draw insights from them?
READ MORE
Information Cascade

Not all data is relevant

Not all data is relevant—in fact, most of it isn’t. Recognizing the fit between the data sources, the analytic tools, and the problem you want to solve is paramount.
READ MORE
Big Data Word Cloud Banner

Why Context Is Critical

Data without context can’t tell you about trends, can’t help you identify patterns and can’t help you make relative assessments to base your decisions on.
READ MORE
Why Context is Critical Banner

Data Normalization

We have previously discussed the challenging process of disambiguation and its importance to developing a high value database that easily yields trustworthy and consistent results. Yet despite all the complexity and work involved in disambiguation, it only gets you part of the way to clean and useful data. The other critical process is called normalization.
READ MORE
Normalization Banner, Medmeme

How is Disambiguation Done?

Disambiguation is the process of looking for clues that will give you enough confidence to match records together from different sources. Rarely is one clue enough you give you sufficient confidence. Similarly, some clues are more important than others.
READ MORE
Diambiguation-Photo

Medmeme to become Pharmaspectra

A new company with a broader mission and product set, the name Pharmaspectra better communicates our goal of solving problems across the biopharma spectrum, from drug discovery through post-marketing.
READ MORE
Medmeme to become Pharmaspectra

Pharmacy Benefit Managers Targeted by Gottlieb

Pharmacy benefits managers (PBMs), private firms that contract with health insurers to process and administer claims, are an integral part of the current pharmaceutical administration process. However, some of the current practices of PBMs have drawn significant criticism.
READ MORE
Pharmacy Benefit Managers Targeted by Gottlieb

8 Red Flags of a Predatory Medical Conference

Bogus data. Pay-for-play. And even fake news. Illegitimate science has taken several forms. The most notable of all: predatory publishing. But another, less discussed, issue is the problem of predatory medical conferences. And there are costs.
READ MORE
8 Red Flags of a Predatory Medical Conference

Characteristics of the Younger MD

A key demographic trend has begun to play out in medicine: a wave of younger doctors entering the field. there’s been an uptick in the number of physicians under age 40, along with an 8 percent spike in medical school enrollments between 2012 and 2016, but what sets them apart?
READ MORE
Characteristics of the Younger MD

What New FDA Guidance Documents May Mean for Pharma

Back in October, the Food and Drug Administration (FDA) published a series of documents regarding Abbreviated New Drug Applications (ANDAs) for the “genericization” of drugs, with an emphasis placed on simplifying the process by which companies can produce generic versions of complex drugs. Here is your guide.
READ MORE
What New FDA Guidance Documents May Mean for Pharma

Kymriah and the Outcomes-Based Contract: Is this a Trend?

Is the outcomes based contract agreed for Kymriah the beginning of a trend? The one-time drug has a hefty price tag of $475,000, but Novartis will only receive payment from CMS if patients show significant improvement. Are these contracts a good way of sharing risk and ensuring wider access to novel therapies?
READ MORE
Kymriah and the Outcomes-Based Contract: Is this a Trend?

The Medical Continuum

Safe Harbor prohibits much of the communication between commercial operations and Medical Affairs; publication planners may not be able to easily access the R&D work that has come before; regional affiliates may be presenting posters at meetings independent of headquarters. Can your organization see the full picture?
READ MORE
The Medical Continuum

The Myth of Data Permanence

Data Really Isn’t Permanent Cyber specialists warn that once something appears on the Internet, it’s there forever. That’s probably truer for salacious photos of pop stars than it is for corporate or government data, though. In scientific communications, unless you collect data as it’s published, you may not be able to retrieve the information you want when you need it.
READ MORE
The Myth of Data Permanence - Medmeme

Dedicated Field Medical Metrics

Historically, Medical Affairs has primarily served a supportive role. Today, it’s becoming a strategic advantage. Filtering information and experts helps Field Medical teams reduce their preparation time up to an estimated 75 percent, to maximize valuable resources.
READ MORE
agenda banner

CITATION: PD-L1/PD-1 Inhibitors and Beyond

A peer-reviewed article that appeared in the Journal of Pharmacology and Clinical Research by David Segarnick, PhD and Heather Chien, M.S., explores the current and future landscape of immunotherapy compounds that use the body's own immune system to fight cancer, citing Medmeme data
READ MORE
CITATION:  PD-L1/PD-1 Inhibitors and Beyond

Strategic Metrics Dedicated to Medical Affairs

Metrics that bridge the gap to Medical Affairs 2.0-Historically, decisions for the generation and placement of Medical Affairs data were based on experience and instinct simply because hard, objective information was not available and end-to-end metrics for evaluation simply did not exist. Medical Affairs is in the process of evolving from a traditional support role into a more strategic one that requires a dedicated set of data and analytics
READ MORE
analytics

PRESS: Harnessing the Unrivaled Power of Key Opinion Leaders

This month's Pharmaceutical Market Europe Magazine features a thought leadership article from Medmeme.  The article discusses the importance of Medical Affairs engaging thought leaders and KOLs early  - not waiting until phase III trials - to drive Share of Scientific Voice and successful launches.
READ MORE
PRESS: Harnessing the Unrivaled Power of Key Opinion Leaders

Are You Being Heard?

Is it better for your scientific paper to appear in JAMA or the New England Journal of Medicine? Should you present your research at a specialty meeting like the Annual Meeting of the Society for Immunotherapy of Cancer or choose a more general conference like the American Society of Clinical Oncology (ASCO)? How you answer those questions affects the impact of your scientific dissemination – your ability to present information to key thought leaders and receive attention from the scientific community.
READ MORE
Are You Being Heard?

Never Gonna Give You Up

One thing that data providers are quickly finding out is that maintaining complete, compliant and updated information on Scientific Experts is hard, especially at an enterprise level for a Medical Affairs organization
READ MORE
Never Gonna Give You Up

PRESS: A World of Content, In Context

Medmeme has been featured this week in GEN – Genetic Engineering and Biotechnology News! An in-depth interview with Medmeme’s CEO, Mahesh Naithani, who describes the particular challenges the pharmaceutical industry has in terms of accessing the right data
READ MORE
PRESS: A World of Content, In Context

Big data’s big potential

As the ocean of data gathered from research studies, wearables and medtech continues to spiral, the pharma industry is faced with a conundrum: what data are actually relevant, how can we access them easily and how do we draw insights from them?
READ MORE
Information Cascade

Not all data is relevant

Not all data is relevant—in fact, most of it isn’t. Recognizing the fit between the data sources, the analytic tools, and the problem you want to solve is paramount.
READ MORE
Big Data Word Cloud Banner

Why Context Is Critical

Data without context can’t tell you about trends, can’t help you identify patterns and can’t help you make relative assessments to base your decisions on.
READ MORE
Why Context is Critical Banner

Data Normalization

We have previously discussed the challenging process of disambiguation and its importance to developing a high value database that easily yields trustworthy and consistent results. Yet despite all the complexity and work involved in disambiguation, it only gets you part of the way to clean and useful data. The other critical process is called normalization.
READ MORE
Normalization Banner, Medmeme

How is Disambiguation Done?

Disambiguation is the process of looking for clues that will give you enough confidence to match records together from different sources. Rarely is one clue enough you give you sufficient confidence. Similarly, some clues are more important than others.
READ MORE
Diambiguation-Photo
Medmeme Logo
1359 Broadway, Suite 600
New York, NY 10018
Ⓒ Medmeme, LLC 2017. ALL RIGHTS RESERVED